Our Next Show: Finding Financial Resources for Multiple Myeloma Care
Tuesday, Oct 17, 2017 @ 10 am Pacific, 11 am Mountain, Noon Central, 1 pm…
Author Jenny A
Jenny A
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical trials. Founder of Myeloma Crowd, Myeloma Crowd Radio and the CrowdCare Foundation.
Clinical Trial: SubQ Daratumumab vs. Active Monitoring for High-Risk Smoldering Myeloma Patients
A smoldering myeloma study is open to determine whether subcutaneous daratumumab prolongs progression free survival…
Bluebird Bio Aims to Lengthen and Deepen Responses with Second CAR T Cell Treatment
Bluebird bio has collaborated with Celgene Corporation on CAR T Cell treatments in multiple myeloma. …
Types and Aggressiveness of Myeloma Can Vary by Location in the Body Say UAMS Researchers
As seen on the UAMS Myeloma Institute website. Researchers with the Myeloma Institute at the University of…
November 11, 2017, Myeloma Crowd Round Tables: Jackson, Mississippi
Myeloma Crowd Round Tables are day-long meetings that provide patients and caregivers updated information so…
Allo Transplant Tip: Skip the Azithromycin and Use Another Antibiotic
Allogeneic donor transplant have to carefully watch out for infections following transplant. A lung condition…
Clinical Trial: BiTE Antibody in Myeloma for Relapsed/Refractory Patients
Bi-specfic T-cell engages (also called BiTEs) are coming to myeloma clinical trials. BiTEs are artificial…
Watching Your Lab Results: Relapse or Errant Bands Thanks to Treatment?
Myeloma patients are familiar with the need to watch their M-protein (sometimes called the M-spike)…
New Drug Class from Cellectar Bioscience Shows Responses in Early Relapsed/Refractory Myeloma Studies
Cellectar Bioscience has run a series of early clinical trials using a new drug called…
The Relationship Between Myeloma Expertise and Clinical Outcomes
Does “geography” mean “destiny” when it comes to multiple myeloma? It turns out that being…
Music 2 Fight Myeloma – We Need Your Help to Fund Myeloma Crowd Research During Blood Cancer Awareness Month!
September is Blood Cancer Awareness month and Takeda Oncology is providing a way to help…
Clinical Trial: New Multiple Myeloma BCMA CAR T Cell Trial from Poseida Therapeutics Opens at Sarah Cannon and MD Anderson
A new CAR T Cell Trial is underway this month at Sarah Cannon in Nashville,…
LOTOJA 2017: Richard Hite and the Muscles for Myeloma Team Raise $9,000 for Myeloma Research
By: Richard Hite WE DID IT! It took me 13 hours to ride the 206…
Clinical Trial: CAR T BB21217 in Multiple Myeloma Opens at Sarah Cannon, Nashville, TN
CAR T cell treatments are now entering clinical trials. Celgene has collaborated with Bluebird bio…
Our Next Show: Liquid Biopsies with Irene Ghobrial, MD and Salomon Manier, MD, PhD, Dana Farber, Wednesday, Sept 27 @ Noon EST
Wednesday, Sept 27, 2017 @ 9 am Pacific, 10 am Mountain, 11 am Central, Noon…
First Dual CAR T Cell Treatment on the Horizon for Multiple Myeloma
Many companies now have CAR T cell therapies in development for multiple myeloma. The most…
Full Show: Sugar’s Secret Cloak for Multiple Myeloma Cells with Michael O’Dwyer, NUI Galway
Michael O’Dwyer, MD National University of Ireland Galway Interview Date: August 25, 2017 Summary Why…
Genes That May Predict if Your Myeloma Responds to an Immunomodulator
In a recent retrospective study, top myeloma specialists collaborated to learn if any specific gene signature…
Clinical Trial: Nivolumab, Lenalidomide, and Dexamethasone In High-Risk Smoldering Multiple Myeloma
This research study is evaluating a new immunotherapy drug called “nivolumab” as a possible treatment…
Clinical Trial: Panobinostat, Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
A phase II trial is open at the Fred Hutchinson Cancer Research Center in Seattle,…
Our Next Show: How Sugar Molecules Act as a Multiple Myeloma Smoke Screen with Michael O’Dwyer, MD, NUI Galway, Friday, August 25 @ 11 am Central
Friday, August 25, 2017 @ 9 am Pacific, 10 am Mountain, 11 am Central, Noon…
Eclipse Camp 2017 in Rexburg, Idaho, August 19-21, 2017
To date, the Myeloma Crowd Research Initiative has raised $477,000 towards our $500,000 goal. The…
Stem Cell Transplant’s Impact on Relapsed Myeloma
When proteasome inhibitors (like bortezomib) and immunomodulators (like lenalidomide) were introduced in the early 2000s…
Clinical Trial: Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
Daratumumab is a newer immunotherapy approved by the FDA for relapsed myeloma. Because it has…
Clinical Trial: Myeloma Cell-Targeted Ionizing Radiation Using I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
The radiosensitivity of multiple myeloma is well documented. A new drug in clinical trials called…
Full Show: The Latest in Myeloma Therapy Advances with Sagar Lonial, MD, Winship Cancer Institue, Emory University
Sagar Lonial, MD Winship Cancer Institute Interview Date: July 19, 2017 Summary Recent meetings held…
Blood Cancer Phase I NK Cell Clinical Trial Shows Durable Complete Responses
An immunotherapy called natural killer (NK) cells can be used with your own NK cells…
Clinical Trial: Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma
Smoldering myeloma (SMM) is considered a precursor of multiple myeloma for a percentage of patients.…
Myeloma 101: What is a “Line” of Therapy in Multiple Myeloma?
Many myeloma clinical trials include approval criteria based on the number of “lines” of therapy…
Considerations on Cost and Convenience of Multiple Myeloma Therapy
If you have multiple myeloma, you’re certainly familiar with spending time in the clinic. Some…
Our Next Show: ASCO and EHA Myeloma Meeting Updates with Sagar Lonial, MD, Winship Cancer Institute, Wednesday, July 19 @ 2 pm Eastern
Wednesday, July 19, 2017 @ 11 am Pacific, Noon Mountain, 1 pm Central, 2 pm…
FDA Panel Recommends Approval for Novartis CAR T Cell Treatment in Leukemia
The Food and Drug Administration panel opened the door to widespread use of CAR T…
Hope vs. Hype in New Cancer Therapies
Over the last few years, cancer patients have become ever hopeful that a cure is…
Clinical Trial: For Patients Resistant to Lenalidomide, the Antibody Elotuzumab With the Newer Pomalidomide and Dex for Relapsed/Refractory Myeloma
Since its approval in the fall of 2015, the monoclonal antibody elotuzumab (Empliciti) has been…
Second Study Shows Kyprolis® Improves Overall Survival for Relapsed/Refractory Myeloma
Final results from the Phase III ASPIRE study were published by Amgen showing that carfilzomib…
Patient Power: Progress in Immunotherapies and Precision Medicine
Dr. Hearn Jay Cho of Mount Sinai Hospital joined Andrew Schorr of Patient Power at…
MCRI Update: CAR T Cell Research, University of Würzburg
The Myeloma Crowd funded two key immunotherapy projects as part of the Myeloma Crowd Research…
EHA 2017: Elotuzumab Shows Long-Term Impact in 4-Year Study Follow-Up
Bristol-Myers Squibb presented four year updated data from their ELOQUENT-2 Trial, a trial enrolling 646…
FDA Places Keytruda Multiple Myeloma Studies on Hold
Merck & Co announced today that the FDA had placed a clinical hold on three…
Clinical Trial: Antibody Phase I Study Targeting CD-352 for Relapsed/Refractory Myeloma Patients
A Phase I clinical trial testing an antibody that targets CD-352 is open for multiple…
September 30, 2017, Myeloma Crowd Round Tables: New York, NY
Myeloma Crowd Round Tables are day-long meetings that provide patients and caregivers updated information so…
Myeloma 101: When Does Smoldering Myeloma Become Active Myeloma?
Smoldering myeloma is a precursor stage of multiple myeloma. Historically, smoldering myeloma patients have not…
EHA 2017: Newly Diagnosed Myeloma
Today many newly diagnosed myeloma patients will receive induction therapy and then go to stem…
EHA 2017: The Nature of Long Remissions
“I still haven’t found what I’m looking for.” U2 What makes one patient’s remission longer…
EHA 2017: The Art of Treating Multiple Myeloma
“The arrival of new effective drugs in such a short period of time is making…
EHA 2017: Myeloma Treatment for the Elderly or Transplant Ineligible
Myeloma therapy is getting better for elderly patients according to Graham Jackson, MD and Professor…
EHA 2017: Managing Myeloma Drug Side Effects
Today is the first day of the European Hematology Conference in Madrid, Spain. We will…
Full Show: New Bi-Specific Antibody Hitting Two Targets in Myeloma, Dirk Hose, MD and Anja Seckinger, MD, University of Heidelberg
Dirk Hose, MD Anja Seckinger, MD Interview Date: May 24, 2017 Summary Many myeloma patients…
ASCO 2017: Three Studies for Newly Diagnosed Multiple Myeloma
Three studies were reported on at the recent ASCO 2017 conference that were specific to…
A Cancer Caregiver’s Open Letter to Family and Friends: Please Understand, Life After Cancer is Different
Every patient agrees that once you’ve been diagnosed with cancer, there is no going back…